Replies to post #18640 on Todos Med Ltd (TOMDF)

[theswordman]

So a lil light on CEO comments if it helps.

The 1.4 BILLION $$ was this--https://www.hhs.gov/about/news/2023/08/22/funding-1-billion-vaccine-clinical-trials-326-million-new-monoclonal-antibody-100-million-explore-novel-vaccine-therapeuti-technologies.html. You can read where it went--not much toward therapeutics. I never know if this is U.S. based companies only but wish Todos would apply for any and all therapeutic trial or funding or whatever

The 3PL is 3rd party logistics (IMHO)--usually for backorders and inventory/stocking etc

The CID Journ article is "accepted" and members only to view. It is about a patient that was treated with long/repeat courses of Pax (and remdesevir/realdeathsevere)
as it says--"clinical and virologic failure". We need to hope this will only ever be in that 1 person. Not sure if this was 1st primary Dr or 9th Dr utilized--but failure pretty much sums it up.

[GreeseMonkey]

I recall Gerald mentioning the difference in 3CL binding sites of Paxlovid vs Tollovid/Tollovir in a number of presentations. He stated back then that Paxlovid was based on earlier work by Dr. Arad's team, and that her later discoveries were used for formulation of Tollovid/Tollovir and it was a better solution than her earlier work. He stated that any viral mutations that occurred were more likely to impact the Paxlovid binding site and unlikely to impact the Tollovid/Tollovir binding site. I feel confident Gerald would only make this claim if Dr. Arad fully agreed.

Now we are starting to see mutations impacting the Paxlovid binding site to make the drug less effective. This may drive further testing and trials toward Tollovid/Tollovir if the mutations are not impacting its effectiveness.